BioSpace News Archive

Synaptogenix, Inc. (Nasdaq: SNPX) (“the Company”), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it has completed enrolling its target of 100 patients for its ongoing National Institutes of Health (“NIH”) sponsored Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer’s disease (“AD”).

Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing.

Horizon Therapeutics plc announced the kickoff of the second annual global innovation challenge, The Horizon Prize powered by MIT Solve.

BioFlyte, a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced that it raised $6.1M in new financing led by Cottonwood Technology Fund with additional funding from existing investor Anzu Partners.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that comprises its pancreatic cancer clinical trial product candidate does not cause systemic toxicity.

Therapeutic Solutions International announced today data demonstrating its JadiCell™ adult stem cell product induces multiplication of specific lung cells which are believed to give rise to new lung tissue which compensate for damaged cells.

Cosmos Holdings, Inc. provided a business update and reported financial results for the year ended December 31, 2021.

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that it submitted an Investigational New Drug Application (IND) for an observational study to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

As a member of the initiative, Pangaea will apply its novel unsupervised natural language processing, natural language generation and automatic machine learning frameworks to address important issues in healthcare in a privacy preserving manner.

nticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that their Founder, President and CEO, Dun Yang, PhD has been named as a 2022 In Vivo Rising Leader.